Factor IX as Adjunctive Therapy to Emicizumab (EMIX)
Status:
Not yet recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
This trial will enroll patients with severe hemophilia A. Experiments will be run in vitro by
spiking patients' blood with different molecules (currently used and theoretically proposed
as adjunctive therapy to emicizumab), therefore no more than minimal direct risk to patients
is expected. This is a pilot preclinical study.